Case Report: Tislelizumab combined with bevacizumab in the treatment of primary malignant pericardial mesothelioma
-
By
-
Zijuan Liu
-
Yating Yan
-
Caihong Jiang
-
June 16, 2026
-
Clinical Scorecard: Clinical Case Study: The Efficacy of Tislelizumab and Bevacizumab in Managing Primary Malignant Pericardial Mesothelioma
At a Glance
| Category | Detail |
|---|
| Condition | |
| Key Mechanisms | |
| Target Population | Patients with primary malignant pericardial mesothelioma, particularly those intolerant to pemetrexed and platinum-based chemotherapy. |
| Care Setting | |
Key Highlights
- PMPM is a rare and highly malignant tumor with a prevalence of less than 0.002%.
- The patient experienced significant symptom relief after 29.4 months of treatment with tislelizumab and bevacizumab.
- Imaging assessments indicated stable disease with no severe adverse reactions leading to mortality.
Guideline-Based Recommendations
Diagnosis
- Diagnosis should involve imaging studies such as PET-CT and histological examination.
Management
- Consider combination therapy with tislelizumab and bevacizumab for patients unable to tolerate standard chemotherapy.
Monitoring & Follow-up
- Regular imaging assessments to evaluate disease stability and symptom management.
Risks
- Potential for grade II bone marrow suppression and skin reactions.
Patient & Prescribing Data
Tislelizumab and bevacizumab may provide symptom relief and disease stability in patients intolerant to other chemotherapies.
Clinical Best Practices
- Utilize a multidisciplinary approach for diagnosis and management of PMPM.
- Monitor for adverse effects during treatment with immune checkpoint and VEGF inhibitors.
Related Resources & Content
